CuraGen Announces Initiation of Phase II Trial of CR011-vcMMAE in Patients with Advanced Bre...('o'getLinkName('Company Sanpshot')); CR...),Health
| HOME >> MEDICINE >> TECHNOLOGY |
'o',getLinkName('Company Sanpshot'));" >CRGN) is a dedicated clinical-stage biopharmaceutical company developing diverse approaches for the treatment of cancer. CuraGen Corporation is headquartered in Branford, Connecticut. For additional information please visit http://www.curagen.com.
Safe Harbor
Statements in this press release regarding management's future
expectations, beliefs, intentions, goals, strategies, plans or prospects,
including statements relating to the effectiveness of antibody-drug
conjugates and CuraGen's CR011-vcMMAE program, including the use of
CR011-vcMMAE for breast cancer, melanoma and gliomas, and the timeframe of
initiating clinical trials and presenting results on CR011-vcMMAE may
constitute forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking statements can be
identified by terminology such as "anticipate," "believe," "could," "could
increase the likelihood," "estimate," "expect," "intend," "is planned,"
"may," "should," "will," "will enable," "would be expected," "look
forward," "may provide," "would" or similar terms, variations of such terms
or the negative of those terms. Such forward-looking statements involve
known and unknown risks, uncertainties and other factors including the risk
that any one or more of CuraGen's drug development programs will not
proceed as planned for technical, scientific or commercial reasons or due
to patient enrollment issues or based on new information from nonclinical
or clinical studies or from other sources, the success of competing
products and technologies, CuraGen's stage of development as a
biopharmaceutical company, government regulation and healthcare reform,
technological uncertainty and product development risks, product liability
exposure, uncertainty of additional funding, CuraGen's history of incurring
losses and the uncertainty of achieving profitability, r
'/>"/>
| SOURCE CuraGen Corporation Copyright©2008 PR Newswire. All rights reserved |
Related medicine technology :
1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. CuraGen Announces Top-Line Phase II Results on Velafermin
4. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
5. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
6. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
7. CuraGen Advances CR011-vcMMAE into Phase II
8. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
9. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |